Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.
about
Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyraseDual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.Efficacy and safety of nadifloxacin for bacterial skin infections: results from clinical and post-marketing studies.Accumulation of mutations in both gyrB and parE genes is associated with high-level resistance to novobiocin in Staphylococcus aureus.Contribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae.Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureusActivity of and resistance to moxifloxacin in Staphylococcus aureus.Contribution of topoisomerase IV mutation to quinolone resistance in Mycoplasma genitalium.Association of norB overexpression and fluoroquinolone resistance in clinical isolates of Staphylococcus aureus from Korea.Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections.Quinolones: action and resistance updated.Silver-loaded nanotubular structures enhanced bactericidal efficiency of antibiotics with synergistic effect in vitro and in vivoBacterial DNA replication enzymes as targets for antibacterial drug discovery.Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria.DNA replication proteins as potential targets for antimicrobials in drug-resistant bacterial pathogens.Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones.In vitro activity of the new quinolone WCK 771 against staphylococci.In Vitro Activities and Spectrum of the Novel Fluoroquinolone Lascufloxacin (KRP-AM1977).Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.Biological profiling of novel tricyclic inhibitors of bacterial DNA gyrase and topoisomerase IV.Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.Bacterial cell killing mediated by topoisomerase I DNA cleavage activity.Dual effectiveness of Alternaria but not Fusarium mycotoxins against human topoisomerase II and bacterial gyrase.Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance.Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureusContribution of the C-8-methoxy group of gatifloxacin to inhibition of type II topoisomerases of Staphylococcus aureus.Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones.Gatifloxacin biodegradable implant for treatment of experimental osteomyelitis: in vitro and in vivo evaluation.Effect of diclofenac on ocular levels of ciprofloxacin and lomefloxacin in rabbits with endophthalmitis.Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics.Emerging fluoroquinolone resistance in Streptococcus agalactiae in South Korea
P2860
Q24567584-BE699A93-7A77-4710-82E8-A662E5153A65Q33770013-B1CBE171-6C94-4A05-A8A0-DEA9D5BC6070Q34142238-8BA6A911-E024-4829-A0D9-FCE6426A59C8Q34438041-E68519FC-6CAE-4719-A0B3-695805BC4E64Q34446438-EDE75BE1-AA26-428D-8F18-1AB2129A0599Q34721556-BB741D4E-D07D-42D2-BE2B-C41DE331BDD7Q34725095-338F7105-AEC8-4D55-B6D2-1916848420F5Q34885313-2D1C70AA-0E8F-4331-91D1-8088D9A901EEQ36757682-883E8D52-67BA-4E4E-923B-C91E3F9B0203Q37286906-73354962-3853-45AF-8CE9-6F3E710CAD8EQ37577369-90049B34-A9AD-4CB8-B6E8-CEF499604AAAQ37595559-239A4D20-1384-4A6D-B92D-3F4F927992EFQ37623987-576171AC-4F93-4D6B-8222-60E901262879Q37998090-13B8250E-6344-477D-90B0-D180827728DBQ38949284-ACBDA47F-84DA-4F6F-AEBF-FFA9FEEAFE43Q39078552-B4A4373B-17CD-463D-969A-BAC8C219BA74Q39652375-A4B03CB9-3503-48AF-A7B9-2C61AFB42BD4Q39955054-7A3C095B-5D9F-4DA4-81C5-C3A561A69CDFQ40287328-EB4C5203-BD72-473B-895C-874CBDD0FA4CQ40424644-B579ADF0-326D-4574-B6B2-78DB9931C2C4Q40733777-1ADA10D8-CD6D-4C6C-9865-1D3E2CB890EDQ40882790-7DC3044A-64D0-4015-9088-E272435F515AQ41456897-C500B5A0-F09D-4095-87D8-133ADCD92E83Q42314511-C23A2B28-7CD4-436A-B293-76DF8D8305D3Q42408718-3F36FEC8-F470-4BC8-B71A-7F0A4F7AFAE3Q42624603-1426C697-BFAC-4909-8660-9EF038AF7DFEQ42784827-877B9764-F25A-4FC9-9368-A5F11CC04500Q43251107-A7A286B3-080F-439D-9C93-2E7689DF4FC4Q43702603-D8D1070B-83CD-407A-A752-56B4FF1A97C5Q44907582-FAD3B44C-26F5-4603-BBA8-6EF3A36E4400Q54358881-43BD1F72-5BAF-4704-BBD6-6F3212E83425Q57213960-DFF49CAB-1124-478C-B227-19B0B5E45653
P2860
Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Target preference of 15 quinol ...... ivities and target inhibition.
@ast
Target preference of 15 quinol ...... ivities and target inhibition.
@en
type
label
Target preference of 15 quinol ...... ivities and target inhibition.
@ast
Target preference of 15 quinol ...... ivities and target inhibition.
@en
prefLabel
Target preference of 15 quinol ...... ivities and target inhibition.
@ast
Target preference of 15 quinol ...... ivities and target inhibition.
@en
P2093
P2860
P1476
Target preference of 15 quinol ...... ivities and target inhibition.
@en
P2093
P2860
P304
P356
10.1128/AAC.45.12.3544-3547.2001
P407
P577
2001-12-01T00:00:00Z